Apellis adds Dr. Mikael Dolsten as independent Class I director

Apellis Pharmaceuticals, Inc.

Dr. Mikael Dolsten elected to Apellis Board as Class I director effective March 1, 2026, serving until the 2027 annual meeting.
Dolsten deemed independent under Nasdaq rules; no committee appointments at this time.
Received initial equity grant: option with $300,000 Black-Scholes value (3-year vest) and RSUs worth $300,000 (1-year cliff vest).
Standard indemnification agreement in place; no family relationships or transactions with the Company.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.